Philip B Mitchell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6202039/publications.pdf

Version: 2024-02-01

457 papers 68,430 citations

90 h-index 246 g-index

481 all docs

481 docs citations

times ranked

481

81416 citing authors

#	Article	IF	CITATIONS
1	In vivo hippocampal subfield volumes in bipolar disorder—A megaâ€analysis from The Enhancing Neuro Imaging Genetics through <scp>Metaâ€Analysis</scp> Bipolar Disorder Working Group. Human Brain Mapping, 2022, 43, 385-398.	3.6	41
2	Intelligence, educational attainment, and brain structure in those at familial highâ€risk for schizophrenia or bipolar disorder. Human Brain Mapping, 2022, 43, 414-430.	3.6	14
3	What we learn about bipolar disorder from largeâ€scale neuroimaging: Findings and future directions from the <scp>ENIGMA</scp> Bipolar Disorder Working Group. Human Brain Mapping, 2022, 43, 56-82.	3.6	67
4	Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders. Biological Psychiatry, 2022, 91, 102-117.	1.3	61
5	Longitudinal Structural Brain Changes in Bipolar Disorder: A Multicenter Neuroimaging Study of 1232 Individuals by the ENIGMA Bipolar Disorder Working Group. Biological Psychiatry, 2022, 91, 582-592.	1.3	29
6	Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors. Biological Psychiatry, 2022, 91, 313-327.	1.3	114
7	Investigating the phenotypic and genetic associations between personality traits and suicidal behavior across major mental health diagnoses. European Archives of Psychiatry and Clinical Neuroscience, 2022, , 1.	3.2	2
8	Using polygenic scores and clinical data for bipolar disorder patient stratification and lithium response prediction: machine learning approach. British Journal of Psychiatry, 2022, 220, 219-228.	2.8	11
9	Stigma in bipolar disorder: A current review of the literature. Australian and New Zealand Journal of Psychiatry, 2022, 56, 1060-1064.	2.3	10
10	Predictors of functional impairment in bipolar disorder: Results from 13 cohorts from seven countries by the global bipolar cohort collaborative. Bipolar Disorders, 2022, 24, 709-719.	1.9	16
11	Strategies and foundations for scientific discovery in longitudinal studies of bipolar disorder. Bipolar Disorders, 2022, 24, 499-508.	1.9	15
12	Longitudinal Changes in Structural Connectivity in Young People at High Genetic Risk for Bipolar Disorder. American Journal of Psychiatry, 2022, 179, 350-361.	7.2	10
13	Genetic variants associated with longitudinal changes in brain structure across the lifespan. Nature Neuroscience, 2022, 25, 421-432.	14.8	75
14	Diagnosis of bipolar disorders and body mass index predict clustering based on similarities in cortical thickness—ENIGMA study in 2436 individuals. Bipolar Disorders, 2022, 24, 509-520.	1.9	5
15	A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?. World Journal of Biological Psychiatry, 2021, 22, 483-494.	2.6	32
16	Brain aging in major depressive disorder: results from the ENIGMA major depressive disorder working group. Molecular Psychiatry, 2021, 26, 5124-5139.	7.9	136
17	Association of polygenic score for major depression with response to lithium in patients with bipolar disorder. Molecular Psychiatry, 2021, 26, 2457-2470.	7.9	44
18	Pre-Employment MMPI-2 Measures and Later Psychological Injury-Related Absenteeism among Police Officers. Policing (Oxford), 2021, 15, 1316-1325.	1.4	1

#	Article	IF	CITATIONS
19	Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. JAMA Psychiatry, 2021, 78, 47.	11.0	136
20	The nature of depression in bipolar disorder. , 2021, , 151-167.		1
21	Prediction of lithium response using genomic data. Scientific Reports, 2021, 11, 1155.	3.3	11
22	Cortical mediation of relationships between dopamine receptor D2 and cognition is absent in youth at risk of bipolar disorder. Psychiatry Research - Neuroimaging, 2021, 309, 111258.	1.8	8
23	Mental health screening amongst police officers: factors associated with under-reporting of symptoms. BMC Psychiatry, 2021, 21, 135.	2.6	26
24	A linkage and exome study of multiplex families with bipolar disorder implicates rare coding variants of ANK3 and additional rare alleles at 10q11-q21. Journal of Psychiatry and Neuroscience, 2021, 46, E247-E257.	2.4	6
25	Association between body mass index and subcortical brain volumes in bipolar disorders–ENIGMA study in 2735 individuals. Molecular Psychiatry, 2021, 26, 6806-6819.	7.9	24
26	Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nature Genetics, 2021, 53, 817-829.	21,4	629
27	Characterisation of age and polarity at onset in bipolar disorder. British Journal of Psychiatry, 2021, 219, 659-669.	2.8	20
28	Breast cancer polygenic risk scores: a 12-month prospective study of patient reported outcomes and risk management behavior. Genetics in Medicine, 2021, 23, 2316-2323.	2.4	14
29	HLA-DRB1 and HLA-DQB1 genetic diversity modulates response to lithium in bipolar affective disorders. Scientific Reports, 2021, 11, 17823.	3.3	10
30	Effects of polygenic risk for suicide attempt and risky behavior on brain structure in young people with familial risk of bipolar disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2021, 186, 485-507.	1.7	4
31	Sertraline hydrochloride for reducing impulsive behaviour in male, repeat-violent offenders (ReINVEST): protocol for a phase IV, double-blind, placebo-controlled, randomised clinical trial. BMJ Open, 2021, 11, e044656.	1.9	0
32	Association of Attention-Deficit/Hyperactivity Disorder and Depression Polygenic Scores with Lithium Response: A Consortium for Lithium Genetics Study. Complex Psychiatry, 2021, 7, 80-89.	0.9	6
33	Combining schizophrenia and depression polygenic risk scores improves the genetic prediction of lithium response in bipolar disorder patients. Translational Psychiatry, 2021, 11, 606.	4.8	25
34	Sertraline hydrochloride for reducing impulsive behaviour in male, repeat-violent offenders (ReINVEST): protocol for a phase IV, double-blind, placebo-controlled, randomised clinical trial. BMJ Open, 2021, 11, e044656.	1.9	8
35	Cover Image, Volume 186B, Number 8, December 2021. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2021, 186, .	1.7	0
36	Using structural MRI to identify bipolar disorders – 13 site machine learning study in 3020 individuals from the ENIGMA Bipolar Disorders Working Group. Molecular Psychiatry, 2020, 25, 2130-2143.	7.9	127

#	Article	IF	Citations
37	Therapeutic drug monitoring of antidepressant and antipsychotic drugs. Handbook of Analytical Separations, 2020, 7, 257-275.	0.8	2
38	Demographic and Clinical Differences Between Bipolar Disorder Patients With and Without Alcohol Use Disorders. Frontiers in Psychiatry, 2020, 11, 570574.	2.6	3
39	Transdiagnostic group cognitive behaviour therapy for anxiety in bipolar disorder—a pilot feasibility and acceptability study. Pilot and Feasibility Studies, 2020, 6, 170.	1.2	3
40	De Novo Gene Variants and Familial Bipolar Disorder. JAMA Network Open, 2020, 3, e203382.	5.9	15
41	Psychosocial implications of living with familial risk of a psychiatric disorder and attitudes to psychiatric genetic testing: A systematic review of the literature. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2020, 183, 277-288.	1.7	5
42	Exploration of experiences with and understanding of polygenic risk scores for bipolar disorder. Journal of Affective Disorders, 2020, 265, 342-350.	4.1	17
43	Striatal Resting-State Connectivity Abnormalities Associated With Different Clinical Stages of Major Depressive Disorder. Journal of Clinical Psychiatry, 2020, 81, .	2.2	14
44	Investigating polygenic burden in age at disease onset in bipolar disorder: Findings from an international multicentric study. Bipolar Disorders, 2019, 21, 68-75.	1.9	20
45	Management Commentary. , 2019, , 246-249.		0
46	Widespread white matter microstructural abnormalities in bipolar disorder: evidence from mega- and meta-analyses across 3033 individuals. Neuropsychopharmacology, 2019, 44, 2285-2293.	5.4	147
47	Junior clinical academic psychiatrists in Australia: The University of New South Wales initiative. Australasian Psychiatry, 2019, 27, 241-244.	0.7	1
48	The Association Between Familial Risk and Brain Abnormalities Is Disease Specific: An ENIGMA-Relatives Study of Schizophrenia and Bipolar Disorder. Biological Psychiatry, 2019, 86, 545-556.	1.3	67
49	Duloxetine effects on striatal restingâ€state functional connectivity in patients with major depressive disorder. Human Brain Mapping, 2019, 40, 3338-3346.	3.6	20
50	Patterns and predictors of family environment among adolescents at high and low risk for familial bipolar disorder. Journal of Psychiatric Research, 2019, 114, 153-160.	3.1	10
51	Genome-wide association study identifies 30 loci associated with bipolar disorder. Nature Genetics, 2019, 51, 793-803.	21.4	1,191
52	Financial Conflicts of Interest and Authorship of Clinical Practice Guidelinesâ€"Trust Is Fragile. JAMA Network Open, 2019, 2, e192840.	5.9	4
53	Metastable brain waves. Nature Communications, 2019, 10, 1056.	12.8	170
54	Psychological interventions for young people at risk for bipolar disorder: A systematic review. Journal of Affective Disorders, 2019, 252, 84-91.	4.1	17

#	Article	IF	CITATIONS
55	A reply to comments by Lee and colleagues on: Repeated intranasal ketamine for treatment resistant depression – the way to go? Results from a pilot randomised controlled trial. Journal of Psychopharmacology, 2019, 33, 260-261.	4.0	0
56	Salivary melatonin onset in youth at familial risk for bipolar disorder. Psychiatry Research, 2019, 274, 49-57.	3.3	8
57	New adolescent grief scales open new research possibilities: A commentary. Death Studies, 2019, 45, 1-2.	2.7	1
58	White matter hyperintensities in young individuals with bipolar disorder or at high genetic risk. Journal of Affective Disorders, 2019, 245, 228-236.	4.1	15
59	A cluster randomized controlled trial of an online psychoeducational intervention for people with a family history of depression. BMC Psychiatry, 2019, 19, 29.	2.6	6
60	Connectomics of bipolar disorder: a critical review, and evidence for dynamic instabilities within interoceptive networks. Molecular Psychiatry, 2019, 24, 1296-1318.	7.9	91
61	Help-seeking experiences of bereaved adolescents: A qualitative study. Death Studies, 2019, 43, 1-8.	2.7	30
62	Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder. JAMA Psychiatry, 2018, 75, 65-74.	11.0	102
63	Aberrant intrinsic functional connectivity in thalamoâ€cortical networks in major depressive disorder. CNS Neuroscience and Therapeutics, 2018, 24, 1063-1072.	3.9	36
64	"Don't bother about me.―The grief and mental health of bereaved adolescents. Death Studies, 2018, 42, 607-615.	2.7	30
65	Fronto-limbic dysconnectivity leads to impaired brain network controllability in young people with bipolar disorder and those at high genetic risk. Neurolmage: Clinical, 2018, 19, 71-81.	2.7	66
66	An examination of multiple classes of rare variants in extended families with bipolar disorder. Translational Psychiatry, 2018, 8, 65.	4.8	35
67	Repeated intranasal ketamine for treatment-resistant depression $\hat{a} \in \text{``the way to go?'}$ Results from a pilot randomised controlled trial. Journal of Psychopharmacology, 2018, 32, 397-407.	4.0	66
68	Structural dysconnectivity of key cognitive and emotional hubs in young people at high genetic risk for bipolar disorder. Molecular Psychiatry, 2018, 23, 413-421.	7.9	48
69	The protocadherin 17 gene affects cognition, personality, amygdala structure and function, synapse development and risk of major mood disorders. Molecular Psychiatry, 2018, 23, 400-412.	7.9	60
70	Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. World Journal of Biological Psychiatry, 2018, 19, 330-348.	2.6	32
71	Prevalence of psychopathology in bipolar high-risk offspring and siblings: a meta-analysis. European Child and Adolescent Psychiatry, 2018, 27, 823-837.	4.7	58
72	Family environment and psychopathology in offspring of parents with bipolar disorder. Journal of Affective Disorders, 2018, 226, 12-20.	4.1	17

#	Article	IF	CITATIONS
73	Clinical predictors of conversion to bipolar disorder in a prospective longitudinal familial high-risk sample: focus on depressive features. Psychological Medicine, 2018, 48, 1713-1721.	4.5	14
74	Gene set enrichment analysis and expression pattern exploration implicate an involvement of neurodevelopmental processes in bipolar disorder. Journal of Affective Disorders, 2018, 228, 20-25.	4.1	14
75	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1789-1858.	13.7	8,569
76	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1859-1922.	13.7	2,123
77	Comprehensive cross-disorder analyses of CNTNAP2 suggest it is unlikely to be a primary risk gene for psychiatric disorders. PLoS Genetics, 2018, 14, e1007535.	3.5	27
78	Mapping cortical brain asymmetry in 17,141 healthy individuals worldwide via the ENIGMA Consortium. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5154-E5163.	7.1	299
79	Analysis of the Influence of microRNAs in Lithium Response in Bipolar Disorder. Frontiers in Psychiatry, 2018, 9, 207.	2.6	28
80	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	12.6	1,085
81	The adolescent grief inventory: Development of a novel grief measurement. Journal of Affective Disorders, 2018, 240, 203-211.	4.1	16
82	Neuropsychological and social cognitive function in young people at genetic risk of bipolar disorder. , 2018, , 157-193.		0
83	Harmful or Helpful? A Systematic Review of How Those Bereaved Through Suicide Experience Research Participation. Crisis, 2018, 39, 364-376.	1.2	25
84	Comments on Cooper etÂal.'s review on strategies to mitigate dissociative and psychotomimetic effects from ketamine when used as a fast-acting antidepressant. World Journal of Biological Psychiatry, 2017, 18, 489-489.	2.6	2
85	Prevalence of exposure to suicide: A meta-analysis of population-based studies. Journal of Psychiatric Research, 2017, 88, 113-120.	3.1	143
86	Can work make you mentally ill? A systematic meta-review of work-related risk factors for common mental health problems. Occupational and Environmental Medicine, 2017, 74, 301-310.	2.8	449
87	A Psychoâ€Educational Intervention for People with a Family History of Depression: Pilot Results. Journal of Genetic Counseling, 2017, 26, 312-321.	1.6	5
88	Pilot Randomized Controlled Trial of Titrated Subcutaneous Ketamine in Older Patients with Treatment-Resistant Depression. American Journal of Geriatric Psychiatry, 2017, 25, 1199-1209.	1.2	85
89	A systematic review of the usefulness of pre-employment and pre-duty screening in predicting mental health outcomes amongst emergency workers. Psychiatry Research, 2017, 253, 129-137.	3.3	26
90	Prevalence of current anxiety disorders in people with bipolar disorder during euthymia: a meta-analysis. Psychological Medicine, 2017, 47, 1107-1115.	4.5	39

#	Article	IF	CITATIONS
91	Traumatic Stress Interacts With Bipolar Disorder Genetic Risk to Increase Risk for Suicide Attempts. Journal of the American Academy of Child and Adolescent Psychiatry, 2017, 56, 1073-1080.	0.5	31
92	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1211-1259.	13.7	5,578
93	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1423-1459.	13.7	284
94	Substance use disorders in adolescent and young adult relatives of probands with bipolar disorder: What drives the increased risk?. Comprehensive Psychiatry, 2017, 78, 130-139.	3.1	6
95	Common variants at $2q11.2$, $8q21.3$, and $11q13.2$ are associated with major mood disorders. Translational Psychiatry, 2017 , 7 , 1273 .	4.8	9
96	Disruptive mood dysregulation disorder, severe mood dysregulation and chronic irritability in youth at high familial risk of bipolar disorder. Australian and New Zealand Journal of Psychiatry, 2017, 51, 1220-1226.	2.3	6
97	Development of a potential screening measure for adolescent depression. Australian and New Zealand Journal of Psychiatry, 2017, 51, 624-633.	2.3	1
98	Functional Dysconnection of the Inferior Frontal Gyrus in Young People With Bipolar Disorder or at Genetic High Risk. Biological Psychiatry, 2017, 81, 718-727.	1.3	126
99	Identification of a Bipolar Disorder Vulnerable Gene CHDH at 3p21.1. Molecular Neurobiology, 2017, 54, 5166-5176.	4.0	9
100	Consistency-based thresholding of the human connectome. NeuroImage, 2017, 145, 118-129.	4.2	157
101	Clinical characteristics of women with reproductive cycle–associated bipolar disorder symptoms. Australian and New Zealand Journal of Psychiatry, 2017, 51, 161-167.	2.3	32
102	Suicidality: prevention, detection and intervention. Australian Prescriber, 2017, 40, 162-166.	1.0	5
103	The Burden of Mental Disorders in the Eastern Mediterranean Region, 1990-2013. PLoS ONE, 2017, 12, e0169575.	2.5	102
104	Is the prevalence of mental illness increasing in Australia? Evidence from national health surveys and administrative data, 2001–2014. Medical Journal of Australia, 2017, 206, 490-493.	1.7	60
105	Identification of shared risk loci and pathways for bipolar disorder and schizophrenia. PLoS ONE, 2017, 12, e0171595.	2.5	77
106	Does perfectionism in bipolar disorder pedigrees mediate associations between anxiety/stress and mood symptoms?. International Journal of Bipolar Disorders, 2017, 5, 34.	2.2	7
107	Altered intrinsic functional brain architecture in female patients with bulimia nervosa. Journal of Psychiatry and Neuroscience, 2017, 42, 414-423.	2.4	20
108	Antidepressant Drugs. Side Effects of Drugs Annual, 2016, 38, 11-19.	0.6	0

#	Article	IF	Citations
109	Study protocol for a systematic review of evidence for lifestyle interventions targeting smoking, sleep, alcohol/other drug use, physical activity, and healthy diet in people with bipolar disorder. Systematic Reviews, 2016, 5, 106.	5.3	9
110	Are there subtypes of bipolar depression?. Acta Psychiatrica Scandinavica, 2016, 134, 260-267.	4.5	6
111	Placeboâ€controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatrica Scandinavica, 2016, 134, 48-56.	4.5	160
112	Abnormalities in left inferior frontal gyral thickness and parahippocampal gyral volume in young people at high genetic risk for bipolar disorder. Psychological Medicine, 2016, 46, 2083-2096.	4.5	25
113	Interhemispheric white matter integrity in young people with bipolar disorder and at high genetic risk. Psychological Medicine, 2016, 46, 2385-2396.	4.5	15
114	Neuropsychological and social cognitive function in young people at genetic risk of bipolar disorder. Psychological Medicine, 2016, 46, 745-758.	4.5	36
115	Workplace interventions for common mental disorders: a systematic meta-review. Psychological Medicine, 2016, 46, 683-697.	4.5	336
116	Is age of onset associated with severity, prognosis, and clinical features in bipolar disorder? A metaâ€analytic review. Bipolar Disorders, 2016, 18, 389-403.	1.9	100
117	Bipolar disorder: defining symptoms and comorbidities. Lancet, The, 2016, 388, 868-869.	13.7	0
118	Genome-wide association study of 40,000 individuals identifies two novel loci associated with bipolar disorder. Human Molecular Genetics, 2016, 25, 3383-3394.	2.9	182
119	The mental health benefits of employment: Results of a systematic meta-review. Australasian Psychiatry, 2016, 24, 331-336.	0.7	236
120	Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet, The, 2016, 387, 1085-1093.	13.7	306
121	Convergent Lines of Evidence Support LRP8 as a Susceptibility Gene for Psychosis. Molecular Neurobiology, 2016, 53, 6608-6619.	4.0	20
122	Impact of a <i>cis</i> -associated gene expression SNP on chromosome 20q11.22 on bipolar disorder susceptibility, hippocampal structure and cognitive performance. British Journal of Psychiatry, 2016, 208, 128-137.	2.8	11
123	Pre- and postloss features of adolescent suicide bereavement: A systematic review. Death Studies, 2016, 40, 229-246.	2.7	40
124	Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis. International Journal of Neuropsychopharmacology, 2016, 19, pyv124.	2.1	175
125	The contribution of geometry to the human connectome. Neurolmage, 2016, 124, 379-393.	4.2	181
126	The History of Bipolar Disorder. Milestones in Drug Therapy, 2016, , 3-16.	0.1	1

#	Article	IF	CITATIONS
127	Confirmatory test of two factors and four subtypes of bipolar disorder based on lifetime psychiatric co-morbidity. Psychological Medicine, 2015, 45, 2181-2196.	4.5	9
128	Assessment of first and second degree relatives of individuals with bipolar disorder shows increased genetic risk scores in both affected relatives and young Atâ€Risk Individuals. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2015, 168, 617-629.	1.7	49
129	Transcranial direct current stimulation to enhance cognition in euthymic bipolar disorder. Bipolar Disorders, 2015, 17, 849-858.	1.9	22
130	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 743-800.	13.7	4,951
131	A web-based preventive intervention program for bipolar disorder: Outcome of a 12-months randomized controlled trial. Journal of Affective Disorders, 2015, 174, 485-492.	4.1	33
132	Shared intermediate phenotypes for schizophrenia and bipolar disorder: neuroanatomical features of subtypes distinguished by executive dysfunction. Journal of Psychiatry and Neuroscience, 2015, 40, 58-68.	2.4	28
133	Bipolar disorder and anxiety: a comorbidity needing better treatments. Lancet Psychiatry, the, 2015, 2, 671-672.	7.4	9
134	Why academic psychiatry is endangered. Australian and New Zealand Journal of Psychiatry, 2015, 49, 9-12.	2.3	25
135	What clinical features precede the onset of bipolar disorder?. Journal of Psychiatric Research, 2015, 62, 71-77.	3.1	41
136	The organisation of the elderly connectome. NeuroImage, 2015, 114, 414-426.	4.2	62
137	Why repetitive transcranial magnetic stimulation should be available for treatment resistant depression. Australian and New Zealand Journal of Psychiatry, 2015, 49, 182-183.	2.3	O
138	Developing a roadmap for the translation of e-mental health services for depression. Australian and New Zealand Journal of Psychiatry, 2015, 49, 776-784.	2.3	73
139	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet, The, 2015, 386, 2145-2191.	13.7	1,544
140	Network dysfunction of emotional and cognitive processes in those at genetic risk of bipolar disorder. Brain, 2015, 138, 3427-3439.	7.6	40
141	Genome-wide analysis implicates microRNAs and their target genes in the development of bipolar disorder. Translational Psychiatry, 2015, 5, e678-e678.	4.8	67
142	Clinical characteristics and temperament influences on †happy†meuphoric and †snappy†irritable bipolar hypo/manic mood states. Journal of Affective Disorders, 2015, 174, 144-149.	4.1	5
143	The effects of antidepressant treatment on restingâ€state functional brain networks in patients with major depressive disorder. Human Brain Mapping, 2015, 36, 768-778.	3.6	154
144	A comparison of schizophrenia, schizoaffective disorder, and bipolar disorder: Results from the Second Australian national psychosis survey. Journal of Affective Disorders, 2015, 172, 30-37.	4.1	44

#	Article	IF	Citations
145	Bereavement After Suicide. Crisis, 2015, 36, 299-303.	1.2	9
146	Comparing the Phenomenology of Depressive Episodes in Bipolar I and II Disorder and Major Depressive Disorder Within Bipolar Disorder Pedigrees. Journal of Clinical Psychiatry, 2015, 76, 32-39.	2.2	34
147	Antidepressant Drugs. Side Effects of Drugs Annual, 2014, 36, 11-25.	0.6	0
148	Rejection sensitivity and pain in bipolar versus unipolar depression. Bipolar Disorders, 2014, 16, 190-198.	1.9	29
149	Cognitive styles and clinical correlates of childhood abuse in bipolar disorder. Bipolar Disorders, 2014, 16, 600-607.	1.9	14
150	Attitudes of medical genetics practitioners and psychiatrists toward communicating with patients about genetic risk for psychiatric disorders. Psychiatric Genetics, 2014, 24, 94-101.	1.1	15
151	Common variant at 16p11.2 conferring risk of psychosis. Molecular Psychiatry, 2014, 19, 108-114.	7.9	85
152	Mindfulness-Based Approaches in the Treatment of Bipolar Disorder: Potential Mechanisms and Effects. Mindfulness, 2014, 5, 186-191.	2.8	11
153	Preferences Regarding Targeted Education and Risk Assessment in People with a Family History of Major Depressive Disorder. Journal of Genetic Counseling, 2014, 23, 785-795.	1.6	11
154	Genome-wide association study reveals two new risk loci for bipolar disorder. Nature Communications, 2014, 5, 3339.	12.8	294
155	Antidepressant drugs. Side Effects of Drugs Annual, 2014, , 27-39.	0.6	0
156	BDNF val66met genotype and schizotypal personality traits interact to influence probabilistic association learning. Behavioural Brain Research, 2014, 274, 137-142.	2.2	8
157	The duration of undiagnosed bipolar disorder: Effect on outcomes and treatment response. Journal of Affective Disorders, 2014, 168, 422-429.	4.1	30
158	Pilot dose–response trial of i.v. ketamine in treatment-resistant depression. World Journal of Biological Psychiatry, 2014, 15, 579-584.	2.6	70
159	Screening for bipolar disorder: Does gender distort scores and case-finding estimates?. Journal of Affective Disorders, 2014, 162, 55-60.	4.1	3
160	A meta-analysis of the risk of major affective disorder in relatives of individuals affected by major depressive disorder or bipolar disorder. Journal of Affective Disorders, 2014, 158, 37-47.	4.1	44
161	Long-Lasting Effects of a Single Subcutaneous Dose of Ketamine for Treating Melancholic Depression: A Case Report. Biological Psychiatry, 2014, 76, e1-e2.	1.3	32
162	Depression and the older medical patientâ€"When and how to intervene. Maturitas, 2014, 79, 153-159.	2.4	34

#	Article	IF	CITATIONS
163	Increase in PAS-induced neuroplasticity after a treatment courseof transcranial direct current stimulation for depression. Journal of Affective Disorders, 2014, 167, 140-147.	4.1	55
164	Characterisation of Genetic Variation in ST8SIA2 and Its Interaction Region in NCAM1 in Patients with Bipolar Disorder. PLoS ONE, 2014, 9, e92556.	2.5	28
165	Exploring Cultureâ€Specific Differences in Beliefs about Causes, Kinship and the Heritability of Major Depressive Disorder: The Views of Angloâ€Celtic and Chineseâ€Australians. Journal of Genetic Counseling, 2013, 22, 613-624.	1.6	3
166	Transcranial direct current stimulation (tDCS) for depression: Analysis of response using a three-factor structure of the Montgomery–Åsberg depression rating scale. Journal of Affective Disorders, 2013, 150, 91-95.	4.1	36
167	Neuroplasticity in Depressed Individuals Compared with Healthy Controls. Neuropsychopharmacology, 2013, 38, 2101-2108.	5.4	149
168	A randomized controlled trial of mindfulnessâ€based cognitive therapy for bipolar disorder. Acta Psychiatrica Scandinavica, 2013, 127, 333-343.	4.5	106
169	The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. American Journal of Psychiatry, 2013, 170, 1249-1262.	7.2	579
170	A factor analytic study in bipolar depression, and response to lamotrigine. CNS Spectrums, 2013, 18, 214-224.	1.2	16
171	Clinical Management of Bipolar Disorder. , 2013, , .		0
172	Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics, 2013, 14, 11-22.	1.4	131
173	Clinical and demographic features associated with the detection of early warning signs in bipolar disorder. Journal of Affective Disorders, 2013, 145, 336-340.	4.1	8
174	Reduced Inferior Frontal Gyrus Activation During Response Inhibition to Emotional Stimuli in Youth at High Risk of Bipolar Disorder. Biological Psychiatry, 2013, 74, 55-61.	1.3	86
175	Anxiety, stress and perfectionism in bipolar disorder. Journal of Affective Disorders, 2013, 151, 1016-1024.	4.1	21
176	The association between meditation practice and treatment outcome in Mindfulness-based Cognitive Therapy for bipolar disorder. Behaviour Research and Therapy, 2013, 51, 338-343.	3.1	89
177	Cognitive regulation of negative affect in schizophrenia and bipolar disorder. Psychiatry Research, 2013, 208, 21-28.	3.3	61
178	Continuation transcranial direct current stimulation for the prevention of relapse in major depression. Journal of Affective Disorders, 2013, 144, 274-278.	4.1	71
179	Ketamine as a new treatment for depression: A review of its efficacy and adverse effects. Australian and New Zealand Journal of Psychiatry, 2013, 47, 710-727.	2.3	100
180	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders. World Journal of Biological Psychiatry, 2013, 14, 334-385.	2.6	480

#	Article	IF	CITATIONS
181	Bipolar disorder in a national survey using the World Mental Health Version of the Composite International Diagnostic Interview: the impact of differing diagnostic algorithms. Acta Psychiatrica Scandinavica, 2013, 127, 381-393.	4.5	46
182	IMPLICATIONS OF THE USE OF GENETIC TESTS IN PSYCHIATRY, WITH A FOCUS ON MAJOR DEPRESSIVE DISORDER: A REVIEW. Depression and Anxiety, 2013, 30, 267-275.	4.1	15
183	Augmenting Transcranial Direct Current Stimulation With D-Cycloserine for Depression. Journal of ECT, 2013, 29, 196-200.	0.6	4
184	Cluster randomized controlled trial of a psycho-educational intervention for people with a family history of depression for use in general practice. BMC Psychiatry, 2013, 13, 325.	2.6	5
185	Studying young people at high genetic risk of bipolar disorder: preparing the ground for future prevention and early intervention. Neuropsychiatry, 2013, 3, 357-361.	0.4	2
186	Re: Bipolar Disorders: A Shift to Overdiagnosis or to Accurate Diagnosis? And Underdiagnosis: Which Way to Measure?. Canadian Journal of Psychiatry, 2013, 58, 372-372.	1.9	1
187	Pharmacological treatment approaches to difficultâ€toâ€treat depression. Medical Journal of Australia, 2013, 199, S44-7.	1.7	6
188	Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report. PLoS ONE, 2013, 8, e65636.	2.5	156
189	Bipolar disorder. Australian Family Physician, 2013, 42, 616-9.	0.5	5
190	Bipolar Disorder: The Shift to Overdiagnosis. Canadian Journal of Psychiatry, 2012, 57, 659-665.	1.9	44
191	Meta-analysis and brain imaging data support the involvement of VRK2 (rs2312147) in schizophrenia susceptibility. Schizophrenia Research, 2012, 142, 200-205.	2.0	48
192	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2197-2223.	13.7	7,061
193	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2163-2196.	13.7	6,376
194	Association between serotonin transporter promoter polymorphisms and psychological distress in a diabetic population. Psychiatry Research, 2012, 200, 343-348.	3.3	10
195	Transcranial direct current stimulation for depression: 3-week, randomised, sham-controlled trial. British Journal of Psychiatry, 2012, 200, 52-59.	2.8	385
196	Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms. Australian and New Zealand Journal of Psychiatry, 2012, 46, 153-160.	2.3	11
197	Lack of cortico-limbic coupling in bipolar disorder and schizophrenia during emotion regulation. Translational Psychiatry, 2012, 2, e90-e90.	4.8	103
198	Treatment of Major Depressive Disorder by Transcranial Random Noise Stimulation: Case Report of a Novel Treatment. Biological Psychiatry, 2012, 72, e9-e10.	1.3	25

#	Article	IF	Citations
199	Antidepressant drugs. Side Effects of Drugs Annual, 2012, , 17-24.	0.6	1
200	Identification of Sialyltransferase 8B as a Generalized Susceptibility Gene for Psychotic and Mood Disorders on Chromosome 15q25-26. PLoS ONE, 2012, 7, e38172.	2.5	60
201	Oxytocin as a moderator of hypnotizability. Psychoneuroendocrinology, 2012, 37, 162-166.	2.7	44
202	Practitioner characteristics and the treatment of children and adolescents with attention deficit hyperactivity disorder. Journal of Paediatrics and Child Health, 2012, 48, 483-489.	0.8	7
203	Adaptive Associations between Social Cognition and Emotion Regulation are Absent in Schizophrenia and Bipolar Disorder. Frontiers in Psychology, 2012, 3, 607.	2.1	56
204	Pharmacological treatment approaches to difficult-to-treat depression. Medical Journal of Australia, 2012, 1, 44-47.	1.7	0
205	A Consensus Statement for Safety Monitoring Guidelines of Treatments for Major Depressive Disorder. Australian and New Zealand Journal of Psychiatry, 2011, 45, 712-725.	2.3	41
206	Funding for mental health research: the gap remains. Medical Journal of Australia, 2011, 195, 681-684.	1.7	40
207	Portrayal of psychiatric genetics in Australian print news media, 1996–2009. Medical Journal of Australia, 2011, 195, 401-404.	1.7	6
208	Ask the Experts: How are we currently dealing with bipolar disorder and what changes are occurring?. Neuropsychiatry, 2011, 1, 533-536.	0.4	0
209	Pain and rejection sensitivity in bipolar depression. Bipolar Disorders, 2011, 13, 59-66.	1.9	13
210	Cognitive regulation of emotion in bipolar I disorder and unaffected biological relatives. Acta Psychiatrica Scandinavica, 2011, 124, 307-316.	4.5	65
211	Psychiatric and genetic studies of binocular rivalry: an endophenotype for bipolar disorder?. Acta Neuropsychiatrica, 2011, 23, 37-42.	2.1	27
212	Physical treatments for bipolar disorder: A review of electroconvulsive therapy, stereotactic surgery and other brain stimulation techniques. Journal of Affective Disorders, 2011, 132, 1-13.	4.1	82
213	Fronto-extracephalic transcranial direct current stimulation as a treatment for major depression: An open-label pilot study. Journal of Affective Disorders, 2011, 134, 459-463.	4.1	94
214	Mindfulness, response styles and dysfunctional attitudes in bipolar disorder. Journal of Affective Disorders, 2011, 134, 126-132.	4.1	19
215	Community attitudes to genetic susceptibility-based mental health interventions for healthy people in a large national sample. Journal of Affective Disorders, 2011, 134, 280-287.	4.1	9
216	Genome-wide Association Study Identifies Genetic Variation in Neurocan as a Susceptibility Factor for Bipolar Disorder. American Journal of Human Genetics, 2011, 88, 372-381.	6.2	257

#	Article	IF	Citations
217	Avoiding skin burns with transcranial direct current stimulation: preliminary considerations. International Journal of Neuropsychopharmacology, 2011, 14, 425-426.	2.1	81
218	Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nature Genetics, 2011, 43, 977-983.	21.4	1,283
219	Hypomania Induction in a Patient With Bipolar II Disorder by Transcranial Direct Current Stimulation (tDCS). Journal of ECT, 2011, 27, 256-258.	0.6	53
220	Looking at the causes of, and possible treatments for, psychiatric diseases: gene–environment interactions, circadian rhythms and neuronal dysfunction. Therapeutic Advances in Chronic Disease, 2011, 2, 5-8.	2.5	0
221	Affective and Anxiety Disorders and their Relationship with Chronic Physical Conditions in Australia: Findings of the 2007 National Survey of Mental Health and Wellbeing. Australian and New Zealand Journal of Psychiatry, 2011, 45, 939-946.	2.3	43
222	Community interest in predictive genetic testing for susceptibility to major depressive disorder in a large national sample. Psychological Medicine, 2011, 41, 1605-1613.	4.5	34
223	Comparison of depressive episodes in bipolar disorder and in major depressive disorder within bipolar disorder pedigrees. British Journal of Psychiatry, 2011, 199, 303-309.	2.8	70
224	Antidepressant drugs. Side Effects of Drugs Annual, 2011, 33, 25-38.	0.6	0
225	Public interest in predictive genetic testing, including direct-to-consumer testing, for susceptibility to major depression: preliminary findings. European Journal of Human Genetics, 2010, 18, 47-51.	2.8	75
226	Assessing oxidative pathway genes as risk factors for bipolar disorder. Bipolar Disorders, 2010, 12, 550-556.	1.9	36
227	Diagnosis and monitoring of bipolar disorder in general practice. Medical Journal of Australia, 2010, 193, S10-3.	1.7	18
228	Reducing Impulsivity in Repeat Violent Offenders: An Open Label Trial of a Selective Serotonin Reuptake Inhibitor. Australian and New Zealand Journal of Psychiatry, 2010, 44, 1137-1143.	2.3	45
229	Induction of Hypomanic Episode With Transcranial Direct Current Stimulation. Journal of ECT, 2010, 26, 68-69.	0.6	47
230	A sham-controlled trial of left and right temporal rTMS for the treatment of auditory hallucinations. Psychological Medicine, 2010, 40, 541-546.	4.5	63
231	Course and Outcome of Bipolar Disorder. Current Topics in Behavioral Neurosciences, 2010, 5, 1-18.	1.7	2
232	Predictive and Diagnostic Genetic Testing in Psychiatry. Psychiatric Clinics of North America, 2010, 33, 225-243.	1.3	24
233	Predictive and Diagnostic Genetic Testing in Psychiatry. Clinics in Laboratory Medicine, 2010, 30, 829-846.	1.4	21
234	Two-Dimensional Genome Scan Identifies Multiple Genetic Interactions in Bipolar Affective Disorder. Biological Psychiatry, 2010, 67, 478-486.	1.3	20

#	Article	IF	Citations
235	Winds of change: growing demands for transparency in the relationship between doctors and the pharmaceutical industry. Medical Journal of Australia, 2009, 191, 273-275.	1.7	18
236	Review of the Quality of Information on Bipolar Disorder on the Internet. Australian and New Zealand Journal of Psychiatry, 2009, 43, 934-945.	2.3	35
237	Issues concerning feedback about genetic testing and risk of depression. British Journal of Psychiatry, 2009, 194, 404-410.	2.8	31
238	Characteristics of Bipolar Disorder in an Australian Specialist Outpatient Clinic: Comparison Across Large Datasets. Australian and New Zealand Journal of Psychiatry, 2009, 43, 109-117.	2.3	46
239	Does oxytocin influence the early detection of angry and happy faces?. Psychoneuroendocrinology, 2009, 34, 220-225.	2.7	105
240	A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology, 2009, 34, 917-923.	2.7	346
241	Chronic neuropathic pain alleviation after transcranial direct current stimulation to the dorsolateral prefrontal cortex. Brain Stimulation, 2009, 2, 149-151.	1.6	14
242	A genome screen of 35 bipolar affective disorder pedigrees provides significant evidence for a susceptibility locus on chromosome 15q25-26. Molecular Psychiatry, 2009, 14, 492-500.	7.9	24
243	Pain during depression and relationship to rejection sensitivity. Acta Psychiatrica Scandinavica, 2009, 119, 375-382.	4.5	37
244	The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disorders, 2009, 11, 453-473.	1.9	401
245	Transcranial Direct Current Stimulation Priming of Therapeutic Repetitive Transcranial Magnetic Stimulation. Journal of ECT, 2009, 25, 256-260.	0.6	26
246	Recent progress in the pharmacotherapy of bipolar disorder. Future Neurology, 2009, 4, 493-508.	0.5	0
247	Association between the serotonin 2A receptor gene and bipolar affective disorder in an Australian cohort. Psychiatric Genetics, 2009, 19, 244-252.	1.1	18
248	Community attitudes towards mental health interventions for healthy people on the basis of genetic susceptibility. Australian and New Zealand Journal of Psychiatry, 2009, 43, 1070-1076.	2.3	6
249	Management commentary. , 2008, , 244-246.		0
250	Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. Depression and Anxiety, 2008, 25, 46-54.	4.1	30
251	Diagnostic guidelines for bipolar disorder: a summary of the <i>International Society for Bipolar Disorders </i> I) Diagnostic Guidelines Task Force Report. Bipolar Disorders, 2008, 10, 117-128.	1.9	86
252	Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disorders, 2008, 10, 144-152.	1.9	276

#	Article	IF	CITATIONS
253	Uncovering the potential risk of serotonin toxicity in Australian veterans using pharmaceutical claims data. British Journal of Clinical Pharmacology, 2008, 66, 682-688.	2.4	23
254	The empirical redefinition of the psychometric criteria for remission in bipolar disorder. Journal of Affective Disorders, 2008, 106, 153-158.	4.1	78
255	Effects of risperidone on glucose metabolism in Chinese patients with schizophrenia: A prospective study. Journal of Psychiatric Research, 2008, 43, 124-128.	3.1	6
256	Oxytocin Increases Gaze to the Eye Region of Human Faces. Biological Psychiatry, 2008, 63, 3-5.	1.3	765
257	A Randomized Controlled Trial of D-Cycloserine Enhancement of Exposure Therapy for Social Anxiety Disorder. Biological Psychiatry, 2008, 63, 544-549.	1.3	316
258	Oxytocin Enhances the Encoding of Positive Social Memories in Humans. Biological Psychiatry, 2008, 64, 256-258.	1.3	315
259	ECNP consensus meeting. Bipolar depression. Nice, March 2007. European Neuropsychopharmacology, 2008, 18, 535-549.	0.7	131
260	A review of the safety of repetitive transcranial magnetic stimulation as a clinical treatment for depression. International Journal of Neuropsychopharmacology, 2008, 11, 131-147.	2.1	176
261	Clozapine in China. Pharmacopsychiatry, 2008, 41, 1-9.	3.3	73
262	Attitudes to Genetic Testing in Families with Multiple Cases of Bipolar Disorder. Genetic Testing and Molecular Biomarkers, 2008, 12, 233-243.	1.7	44
263	A study using transcranial magnetic stimulation to investigate motor mechanisms in psychomotor retardation in depression. International Journal of Neuropsychopharmacology, 2008, 11, 935-46.	2.1	15
264	Genome screen of 15 Australian bipolar affective disorder pedigrees supports previously identified loci for bipolar susceptibility genes. Psychiatric Genetics, 2008, 18, 156-161.	1.1	5
265	Microarray gene expression profiling of mouse brain mRNA in a model of lithium treatment. Psychiatric Genetics, 2008, 18, 64-72.	1.1	44
266	The Long and the Short of It: Associations Between 5-HTT Genotypes and Coping With Stress. Psychosomatic Medicine, 2007, 69, 614-620.	2.0	38
267	Repetitive transcranial magnetic stimulation for the treatment of obsessive compulsive disorder: a double-blind controlled investigation. Psychological Medicine, 2007, 37, 1645-1649.	4.5	135
268	A sham-controlled trial of the efficacy and safety of twice-daily rTMS in major depression. Psychological Medicine, 2007, 37, 341.	4.5	105
269	Attitudes towards childbearing, causal attributions for bipolar disorder and psychological distress: a study of families with multiple cases of bipolar disorder. Psychological Medicine, 2007, 37, 1601-1611.	4.5	62
270	A randomized controlled trial of the effect of d-cycloserine on extinction and fear conditioning in humans. Behaviour Research and Therapy, 2007, 45, 663-672.	3.1	99

#	Article	IF	Citations
271	Depression and anxiety with rimonabant. Lancet, The, 2007, 370, 1671-1672.	13.7	81
272	Evaluation of an Online Relapse Prevention Program for Bipolar Disorder. Disease Management and Health Outcomes, 2007, 15, 215-224.	0.4	31
273	Gender differences in 542 Chinese inpatients with schizophrenia. Schizophrenia Research, 2007, 97, 88-96.	2.0	84
274	Social inhibition and treatmentâ€resistant depression. Personality and Mental Health, 2007, 1, 62-73.	1.2	5
275	Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia. Bipolar Disorders, 2007, 9, 114-125.	1.9	298
276	The Bipolar Depression Rating Scale (BDRS): its development, validation and utility. Bipolar Disorders, 2007, 9, 571-579.	1.9	126
277	Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia. British Journal of Clinical Pharmacology, 2007, 64, 49-56.	2.4	65
278	Serotonin transporter gene status predicts caudate nucleus but not amygdala or hippocampal volumes in older persons with major depression. Journal of Affective Disorders, 2007, 98, 137-142.	4.1	121
279	Psychomotor slowing in older patients with major depression: Relationships with blood flow in the caudate nucleus and white matter lesions. Psychiatry Research - Neuroimaging, 2007, 155, 211-220.	1.8	43
280	A randomized controlled trial of the effect of d-cycloserine on exposure therapy for spider fear. Journal of Psychiatric Research, 2007, 41, 466-471.	3.1	142
281	Life events, first depression onset and the serotonin transporter gene. British Journal of Psychiatry, 2006, 188, 210-215.	2.8	262
282	Emerging drugs for bipolar disorder. Expert Opinion on Emerging Drugs, 2006, 11, 621-634.	2.4	5
283	The management of bipolar disorder in general practice. Medical Journal of Australia, 2006, 184, 566-570.	1.7	13
284	Evidence into practice: the mental health hurdle is high. Medical Journal of Australia, 2006, 185, 295-295.	1.7	0
285	Altered gene expression in mice treated with the mood stabilizer sodium valproate. International Journal of Neuropsychopharmacology, 2006, 9, 267.	2.1	25
286	Positional cloning, association analysis and expression studies provide convergent evidence that the cadherin gene FAT contains a bipolar disorder susceptibility allele. Molecular Psychiatry, 2006, 11, 372-383.	7.9	59
287	Transcranial Magnetic Stimulation for Depression. Australian and New Zealand Journal of Psychiatry, 2006, 40, 406-413.	2.3	60
288	Transcranial magnetic stimulation for depression. Australian and New Zealand Journal of Psychiatry, 2006, 40, 406-413.	2.3	3

#	Article	IF	Citations
289	"Getting physical": the management of neuropsychiatric disorders using novel physical treatments. Neuropsychiatric Disease and Treatment, 2006, 2, 165-179.	2.2	12
290	A Randomized Controlled Trial of Cognitive Therapy for Bipolar Disorder. Journal of Clinical Psychiatry, 2006, 67, 277-286.	2.2	167
291	Bipolar disorder 40 years ago: a critical period of transition. Australian and New Zealand Journal of Psychiatry, 2006, 40, 279-80.	2.3	1
292	When Euthymia Is Just Not Good Enough. Journal of Nervous and Mental Disease, 2005, 193, 323-330.	1.0	69
293	Reduced hippocampal volumes and memory loss in patients with early- and late-onset depression. British Journal of Psychiatry, 2005, 186, 197-202.	2.8	389
294	Identification, characterization, and association analysis of novel genes from the bipolar disorder susceptibility locus on chromosome 4q35. Psychiatric Genetics, 2005, 15, 199-204.	1.1	2
295	The epidemiology of bipolar disorder: sociodemographic, disability and service utilization data from the Australian National Study of Low Prevalence (Psychotic) Disorders. Bipolar Disorders, 2005, 7, 326-337.	1.9	111
296	Executive functioning and theory of mind in euthymic bipolar disorder. Bipolar Disorders, 2005, 7, 43-52.	1.9	128
297	Transcranial magnetic stimulation for the deficit syndrome of schizophrenia: A pilot investigation. Psychiatry and Clinical Neurosciences, 2005, 59, 354-357.	1.8	55
298	Progressing a spectrum model for defining non-melancholic depression. Acta Psychiatrica Scandinavica, 2005, 111, 139-143.	4.5	12
299	Treatment-resistant depression: resistant to definition?. Acta Psychiatrica Scandinavica, 2005, 112, 302-309.	4.5	83
300	Vascular risk and low serum B12 predict white matter lesions in patients with major depression. Journal of Affective Disorders, 2005, 85, 327-332.	4.1	39
301	Great expectations: Factors influencing patient expectations and doctors recommendations at a Mood Disorders Unit. Journal of Affective Disorders, 2005, 88, 187-192.	4.1	10
302	A review of the efficacy of transcranial magnetic stimulation (TMS) treatment for depression, and current and future strategies to optimize efficacy. Journal of Affective Disorders, 2005, 88, 255-267.	4.1	259
303	Implications of genetic risk information in families with a high density of bipolar disorder: an exploratory study. Social Science and Medicine, 2005, 60, 109-118.	3.8	89
304	Relationship between self-reported childhood behavioral inhibition and lifetime anxiety disorders in a clinical sample. Depression and Anxiety, 2005, 22, 103-113.	4.1	111
305	Association analysis of transcripts from the bipolar susceptibility locus on chromosome 4q35, exclusion of a pathogenic role for eight positional candidate genes. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 134B, 56-59.	1.7	4
306	Techniques for the Identification of Genes Involved in Psychiatric Disorders. Australian and New Zealand Journal of Psychiatry, 2005, 39, 542-549.	2.3	2

#	Article	IF	CITATIONS
307	Treatment of bipolar depression: focus on pharmacologic therapies. Expert Review of Neurotherapeutics, 2005, 5, 69-78.	2.8	3
308	Extended-Release Carbamazepine Capsules. CNS Drugs, 2005, 19, 717-718.	5.9	2
309	A Brief Measure of Worry Severity (BMWS): personality and clinical correlates of severe worriers. Journal of Anxiety Disorders, 2005, 19, 877-892.	3.2	72
310	Major advances in bipolar disorder. Medical Journal of Australia, 2004, 181, 207-210.	1.7	18
311	Making new choices about antidepressants in Australia: the long view 1975–2002. Medical Journal of Australia, 2004, 181, S21-4.	1.7	45
312	Implications of Childhood Trauma for Depressed Women: An Analysis of Pathways From Childhood Sexual Abuse to Deliberate Self-Harm and Revictimization. American Journal of Psychiatry, 2004, 161, 1417-1425.	7.2	277
313	Therapeutic drug monitoring of non-tricyclic antidepressant drugs. Clinical Chemistry and Laboratory Medicine, 2004, 42, 1212-8.	2.3	34
314	Cognitive generation of affect in hypomania: an fMRI study. Bipolar Disorders, 2004, 6, 271-285.	1.9	120
315	Bipolar depression: phenomenological overview and clinical characteristics. Bipolar Disorders, 2004, 6, 530-539.	1.9	178
316	Cognitive generation of affect in bipolar depression: an fMRI study. European Journal of Neuroscience, 2004, 19, 741-754.	2.6	158
317	Clinical utility of the modified Stroop task as a treatment outcome measure: Questions raised. Clinical Psychologist, 2004, 8, 76-80.	0.8	10
318	Studying personality characteristics in bipolar depressed subjects: how comparator group selection can dictate results. Acta Psychiatrica Scandinavica, 2004, 109, 376-382.	4.5	6
319	A Randomized Controlled Study of Cognitive Behavior Therapy and Behavioral Family Therapy for Anorexia Nervosa Patients. Eating Disorders, 2004, 12, 303-314.	3.0	140
320	Therapeutic drug monitoring of antidepressant and antipsychotic drugs. Handbook of Analytical Separations, 2004, , 255-271.	0.8	2
321	Twelve-month prevalence and disability of DSM-IV bipolar disorder in an Australian general population survey. Psychological Medicine, 2004, 34, 777-785.	4.5	128
322	Severity of stressful life events in first and subsequent episodes of depression: the relevance of depressive subtype. Journal of Affective Disorders, 2003, 73, 245-252.	4.1	58
323	Distinguishing early and late onset non-melancholic unipolar depression. Journal of Affective Disorders, 2003, 74, 131-138.	4.1	53
324	Prevalence and correlates of DSM-IV major depression in an Australian national survey. Journal of Affective Disorders, 2003, 75, 155-162.	4.1	206

#	Article	IF	Citations
325	Heterogeneity of admission history among patients with bipolar disorder. Journal of Affective Disorders, 2003, 75, 163-170.	4.1	3
326	Genetic refinement and physical mapping of a 2.3 Mb probable disease region associated with a bipolar affective disorder susceptibility locus on chromosome 4q35. American Journal of Medical Genetics Part A, 2003, 117B, 23-32.	2.4	18
327	An Australian validation study of the temperament and character inventory. Acta Psychiatrica Scandinavica, 2003, 108, 359-366.	4.5	29
328	Valid Assessment of the Clinical Features of Depression by Relatives Appears to Slip Under the RADAR. Australian and New Zealand Journal of Psychiatry, 2003, 37, 92-96.	2.3	1
329	Schema-Focused Cognitive Therapy for Bipolar Disorder: Reducing Vulnerability to Relapse Through Attitudinal Change. Australian and New Zealand Journal of Psychiatry, 2003, 37, 41-48.	2.3	62
330	Use of Antidepressants by General Practitioners and Psychiatrists in Australia. Australian and New Zealand Journal of Psychiatry, 2003, 37, 184-189.	2.3	45
331	Summary of Guideline for the Treatment of Bipolar Disorder. Australasian Psychiatry, 2003, 11, 39-53.	0.7	16
332	Major leads in the search for susceptibility genes for depression. Pharmacogenomics Journal, 2003, 3, 305-307.	2.0	0
333	Neuropsychological Performance in Patients With Depression is Associated With Clinical, Etiological and Genetic Risk Factors. Journal of Clinical and Experimental Neuropsychology, 2003, 25, 866-877.	1.3	140
334	Genome Scan Meta-Analysis of Schizophrenia and Bipolar Disorder, Part III: Bipolar Disorder. American Journal of Human Genetics, 2003, 73, 49-62.	6.2	400
335	Bipolar Depression. CNS Drugs, 2003, 17, 9-25.	5.9	63
336	Pharmacotherapy to limit weight gain caused by antipsychotic use. Expert Opinion on Pharmacotherapy, 2003, 4, 1679-1686.	1.8	3
337	Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression. Archives of General Psychiatry, 2003, 60, 1079.	12.3	797
338	Gender differences in response to differing antidepressant drug classes: two negative studies. Psychological Medicine, 2003, 33, 1473-1477.	4.5	70
339	High (15 Hz) and low (1 Hz) frequency transcranial magnetic stimulation have different acute effects on regional cerebral blood flow in depressed patients. Psychological Medicine, 2003, 33, 997-1006.	4.5	93
340	Slow binocular rivalry in bipolar disorder. Psychological Medicine, 2003, 33, 683-692.	4.5	81
341	Double-blind controlled investigation of bilateral prefrontal transcranial magnetic stimulation for the treatment of resistant major depression. Psychological Medicine, 2003, 33, 33-40.	4.5	118
342	Parental Care and Personality in Melancholic and Nonmelancholic Depression. Journal of Nervous and Mental Disease, 2003, 191, 358-364.	1.0	3

#	Article	IF	Citations
343	PARENTAL CARE AND PERSONALITY IN MELANCHOLIC AND NONMELANCHOLIC DEPRESSION. Journal of Nervous and Mental Disease, 2003, 191, 358-364.	1.0	15
344	The Expanding Pharmacopoeia for Bipolar Disorder. Annual Review of Medicine, 2002, 53, 173-188.	12.2	58
345	Atypical Depression: A Reappraisal. American Journal of Psychiatry, 2002, 159, 1470-1479.	7.2	187
346	RECOGNIZING THE ANXIOUS FACE OF DEPRESSION. Journal of Nervous and Mental Disease, 2002, 190, 366-373.	1.0	39
347	Caudate Nucleus Volumes and Genetic Determinants of Homocysteine Metabolism in the Prediction of Psychomotor Speed in Older Persons With Depression. American Journal of Psychiatry, 2002, 159, 2096-2098.	7.2	115
348	Psychiatry. Medical Journal of Australia, 2002, 176, 34-34.	1.7	0
349	Familial idiopathic basal ganglia calcification (Fahr's disease) without neurological, cognitive and psychiatric symptoms is not linked to the IBGC1 locus on chromosome 14q. Human Genetics, 2002, 110, 8-14.	3.8	67
350	A genome screen of 13 bipolar affective disorder pedigrees provides evidence for susceptibility loci on chromosome 3 as well as chromosomes 9, 13 and 19. Molecular Psychiatry, 2002, 7, 594-603.	7.9	23
351	A transcript map encompassing a susceptibility locus for bipolar affective disorder on chromosome 4q35. Molecular Psychiatry, 2002, 7, 867-873.	7.9	10
352	Stylized transcript map of chromosome 4q35 encompassing the locus for a bipolar disorder susceptibility gene. Molecular Psychiatry, 2002, 7, 669-669.	7.9	0
353	Effects of a 2- to 4-week course of repetitive transcranial magnetic stimulation (rTMS) on neuropsychologic functioning, electroencephalogram, and auditory threshold in depressed patients. Biological Psychiatry, 2001, 49, 615-623.	1.3	129
354	Cognitive deficits in depression: Possible implications for functional neuropathology. British Journal of Psychiatry, 2001, 178, 200-206.	2.8	998
355	The differential impact of age on the phenomenology of melancholia. Psychological Medicine, 2001, 31, 1231-1236.	4.5	52
356	Sustained Response to Open-Label Venlafaxine in Drug-Resistant Major Depression. Journal of Clinical Psychopharmacology, 2001, 21, 185-189.	1.4	31
357	Co-prescribing of SSRIs and TCAs in Australia: how often does it occur and who is doing it?. British Journal of Clinical Pharmacology, 2001, 51, 93-98.	2.4	18
358	Depression and Smoking: Examining Correlates in a Subset of Depressed Patients. Australian and New Zealand Journal of Psychiatry, 2001, 35, 329-335.	2.3	18
359	â€~Why Getting Fat, Doc?' Weight Gain and Psychotropic Medications. Australian and New Zealand Journal of Psychiatry, 2001, 35, 315-321.	2.3	31
360	A genome screen of a large bipolar affective disorder pedigree supports evidence for a susceptibility locus on chromosome 13q. Molecular Psychiatry, 2001, 6, 396-403.	7.9	39

#	Article	IF	CITATIONS
361	Therapeutic drug monitoring of psychotropic medications. British Journal of Clinical Pharmacology, 2001, 52, 45-54.	2.4	12
362	Early and late onset depression in old age: different aetiologies, same phenomenology. Journal of Affective Disorders, 2001, 66, 225-236.	4.1	184
363	Therapeutic drug monitoring of psychotropic medications. British Journal of Clinical Pharmacology, 2001, 52, 45-54.	2.4	65
364	Topics in contemporary psychiatric practice: Weight Gain. International Journal of Psychiatry in Clinical Practice, 2001, 5, 295-296.	2.4	1
365	Therapeutic drug monitoring of psychotropic medications. British Journal of Clinical Pharmacology, 2001, 52, 45-54.	2.4	12
366	Stimulus Intensity in Transcranial Magnetic Stimulation (TMS) Studies. Journal of ECT, 2001, 17, 294-295.	0.6	4
367	Right Versus Left Prefrontal Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder. Journal of Clinical Psychiatry, 2001, 62, 981-984.	2.2	111
368	The clinical features of bipolar depression: a comparison with matched major depressive disorder patients. Journal of Clinical Psychiatry, 2001, 62, 212-6; quiz 217.	2.2	64
369	Therapeutic drug monitoring of psychotropic medications. British Journal of Clinical Pharmacology, 2000, 49, 303-312.	2.4	69
370	Predictors of 1-Year Outcome in Depression. Australian and New Zealand Journal of Psychiatry, 2000, 34, 56-64.	2.3	13
371	â€~Acting out' and â€~acting in' behavioural stress responses: the relevance of anxiety and personality style. Journal of Affective Disorders, 2000, 57, 173-177.	4.1	8
372	Do early adverse experiences establish a cognitive vulnerability to depression on exposure to mirroring life events in adulthood?. Journal of Affective Disorders, 2000, 57, 209-215.	4.1	29
373	The nature of bipolar depression: implications for the definition of melancholia. Journal of Affective Disorders, 2000, 59, 217-224.	4.1	97
374	Recent trends in the use of antidepressant drugs in Australia, 1990–1998. Medical Journal of Australia, 2000, 173, 458-461.	1.7	110
375	Transcranial magnetic stimulation (TMS) in controlled treatment studies: are some "sham―forms active?. Biological Psychiatry, 2000, 47, 325-331.	1.3	260
376	Effect of apomorphine on motor and cognitive function in melancholic patients: a preliminary report. Psychiatry Research, 2000, 97, 207-215.	3.3	26
377	Efficacy of Venlafaxine and Predictors of Response in a Prospective Open-Label Study of Patients With Treatment-Resistant Major Depression. Journal of Clinical Psychopharmacology, 2000, 20, 483-487.	1.4	46
378	Lithium treatment for bipolar disorder. Bulletin of the World Health Organization, 2000, 78, 515-7.	3.3	35

#	Article	IF	CITATIONS
379	Twelve-month outcome of nonmelancholic depressive subjects: refinement of subgroups by examination of trajectories. Annals of Clinical Psychiatry, 2000, 12, 219-225.	0.6	0
380	John Cade and the discovery of lithium treatment for manic depressive illness. Medical Journal of Australia, 1999, 171, 262-264.	1.7	15
381	John Cade and Frank Macfarlane Burnet anniversaries. Medical Journal of Australia, 1999, 171, 502-502.	1.7	1
382	On the 50th Anniversary of John Cade's Discovery of the Anti-Manic Effect of Lithium. Australian and New Zealand Journal of Psychiatry, 1999, 33, 623-628.	2.3	6
383	Sub-Grouping Non-Melancholic Major Depression Using Both Clinical and Aetiological Features. Australian and New Zealand Journal of Psychiatry, 1999, 33, 217-225.	2.3	10
384	On the 50th anniversary of John Cade's discovery of the anti-manic effect of lithium*. Australian and New Zealand Journal of Psychiatry, 1999, 33, 623-628.	2.3	17
385	The Comparative Effectiveness of Fixed and Stimulus Dosing Forms of Electroconvulsive Therapy for the Treatment of Unipolar Depression: A †Quality Assurance†Study. Australasian Psychiatry, 1999, 7, 262-263.	0.7	1
386	The place of anticonvulsants and other putative mood stabilisers in the treatment of bipolar disorder. Australian and New Zealand Journal of Psychiatry, 1999, 33, S99-S107.	2.3	11
387	The influence of anxiety as a risk to early onset major depression. Journal of Affective Disorders, 1999, 52, 11-17.	4.1	95
388	Sub-grouping non-melancholic depression from manifest clinical features. Journal of Affective Disorders, 1999, 53, 1-13.	4.1	21
389	Nonparametric simulation-based statistical analyses for bipolar affective disorder locus on chromosome 21q22.3., 1999, 88, 99-102.		34
390	Cognitive function in depression: a distinct pattern of frontal impairment in melancholia?. Psychological Medicine, 1999, 29, 73-85.	4.5	260
391	Subtyping Depression. Journal of Nervous and Mental Disease, 1999, 187, 610-617.	1.0	29
392	St. John's wort - quack medicine or novel antidepressant treatment?. Australian Prescriber, 1999, 22, 112-113.	1.0	2
393	Disordered personality style: higher rates in non-melancholic compared to melancholic depression. Journal of Affective Disorders, 1998, 47, 131-140.	4.1	23
394	A Susceptibility Locus for Bipolar Affective Disorder on Chromosome 4q35. American Journal of Human Genetics, 1998, 62, 1084-1091.	6.2	90
395	Use of Psychotropic Medications in Breastfeeding Women: Acute and Prophylactic Treatment. Australian and New Zealand Journal of Psychiatry, 1998, 32, 778-784.	2.3	28
396	Non-melancholic depression: the contribution of personality, anxiety and life events to subclassification. Psychological Medicine, 1998, 28, 1209-1219.	4.5	35

#	Article	IF	Citations
397	Qualitative and quantitative analyses of a †lock and key' hypothesis of depression. Psychological Medicine, 1998, 28, 1263-1273.	4.5	17
398	Psychotropic medications in pregnant women: treatment dilemmas. Medical Journal of Australia, 1998, 169, 428-431.	1.7	34
399	On Modelling Personality Disorders: Are Personality Style and Disordered Functioning Independent or Interdependent Constructs?. Journal of Nervous and Mental Disease, 1998, 186, 709-715.	1.0	5
400	High levels of Gs alpha in platelets of euthymic patients with bipolar affective disorder. American Journal of Psychiatry, 1997, 154, 218-223.	7.2	57
401	How distinct is â€~distinct quality' of mood?. Psychological Medicine, 1997, 27, 445-453.	4.5	9
402	Increased rate of psychosis and psychomotor change in depression with age. Psychological Medicine, 1997, 27, 1205-1213.	4.5	79
403	Drug Interactions of Clinical Significance with Selective Serotonin Reuptake Inhibitors. Drug Safety, 1997, 17, 390-406.	3.2	70
404	Dysfunctional parenting: over-representation in non-melancholic depression and capacity of such specificity to refine sub-typing depression measures. Psychiatry Research, 1997, 73, 57-71.	3.3	27
405	4. Managing depression in a community setting. Medical Journal of Australia, 1997, 167, 383-388.	1.7	9
406	Plumbing the depths: Some problems in quantifying depression severity. Journal of Affective Disorders, 1997, 42, 49-58.	4.1	7
407	Distinguishing psychotic depression from melancholia. Journal of Affective Disorders, 1997, 42, 155-167.	4.1	21
408	Exclusion of Linkage Between Bipolar Affective Disorder and Chromosome 16 in 12 Australian Pedigrees., 1997, 74, 304-310.		9
409	Parental sex effects in bipolar affective disorder pedigrees. , 1997, 14, 611-616.		4
410	Managing depression in a community setting. Medical Journal of Australia, 1997, 167, 383-8.	1.7	4
411	Depressive psychomotor disturbance, cortisol, and dexamethasone. Biological Psychiatry, 1996, 40, 941-950.	1.3	24
412	Nonlinkage of D6S260, a putative schizophrenia locus, to bipolar affective disorder., 1996, 67, 485-487.		2
413	Biochemical correlates of in vivo cell-mediated immune dysfunction in patients with depression: A preliminary report. International Journal of Immunopharmacology, 1995, 17, 685-690.	1.1	23
414	The early history of convulsive therapies in Australia. Medical Journal of Australia, 1995, 163, 624-627.	1.7	2

#	Article	IF	Citations
415	Fitting the Treatment to the Patient: Recent Advances in the Practice of Electroconvulsive Therapy. Australian and New Zealand Journal of Psychiatry, 1995, 29, 484-491.	2.3	12
416	Subcortical hyperintensities on magnetic resonance imaging: Clinical correlates and prognostic significance in patients with severe depression. Biological Psychiatry, 1995, 37, 151-160.	1.3	395
417	Editorial: The new antidepressants - are they worth the cost?. Australian Prescriber, 1995, 18, 82-84.	1.0	6
418	Novel French antidepressants not available in the United States. Psychopharmacology Bulletin, 1995, 31, 509-19.	0.0	4
419	Treatment Resistant Depression in an Australian Context I: The Utility of the Term and Approaches to Management. Australian and New Zealand Journal of Psychiatry, 1994, 28, 14-22.	2.3	12
420	Treatment Resistant Depression in an Australian Context II: Outcome of a Series of Patients. Australian and New Zealand Journal of Psychiatry, 1994, 28, 23-33.	2.3	17
421	Patient Satisfaction with a Mood Disorders Unit: Elements and Components. Australian and New Zealand Journal of Psychiatry, 1994, 28, 279-287.	2.3	22
422	Combining Lithium and Sodium Valproate for Bipolar Disorder. Australian and New Zealand Journal of Psychiatry, 1994, 28, 141-143.	2.3	21
423	Exclusion of close linkage of bipolar disorder to the Gs-α subunit gene in nine Australian pedigrees. Journal of Affective Disorders, 1994, 32, 187-195.	4.1	30
424	A brief self-report depression measure assessing mood state and social impairment. Journal of Affective Disorders, 1994, 30, 133-142.	4.1	16
425	Major depression: The validity of a diagnosis. Depression, 1993, 1, 180-180.	0.6	0
426	Inter-rater reliability of a refined index of melancholia: the CORE system. Journal of Affective Disorders, 1993, 27, 155-162.	4.1	18
427	Exclusion of close linkage of bipolar disorder to the dopamine D3 receptor gene in nine Australian pedigrees. Journal of Affective Disorders, 1993, 27, 213-224.	4.1	22
428	Psychomotor disturbance in depression: defining the constructs. Journal of Affective Disorders, 1993, 27, 255-265.	4.1	87
429	Specificity of interpersonal sensitivity to non-melancholic depression. Journal of Affective Disorders, 1993, 27, 101-105.	4.1	54
430	Chlorpromazine Turns Forty. Australian and New Zealand Journal of Psychiatry, 1993, 27, 370-373.	2.3	21
431	Lessons from a Mood Disorders Unit. Australian and New Zealand Journal of Psychiatry, 1993, 27, 254-263.	2.3	23
432	The Genetics of Bipolar Disorder. Australian and New Zealand Journal of Psychiatry, 1993, 27, 560-580.	2.3	14

#	Article	IF	CITATIONS
433	An Australian Multicentre Study of Moclobemide versus Amitriptyline in the Treatment of Depression. Australian and New Zealand Journal of Psychiatry, 1992, 26, 454-458.	2.3	7
434	Monoamine Oxidase Inhibitors (MAOI) or Reversible Inhibitors of Monoamine Oxidase (RIMA)/Tricyclic Antidepressant (TCA) Combination Therapy. Australian and New Zealand Journal of Psychiatry, 1992, 26, 327-329.	2.3	7
435	Comparison of clinician rated and family corroborative witness data for depressed patients. Journal of Affective Disorders, 1992, 24, 25-34.	4.1	11
436	Are there any differences between bipolar and unipolar melancholia?. Journal of Affective Disorders, 1992, 25, 97-105.	4.1	68
437	Exclusion of close linkage of bipolar disorder to dopamine D1 and D2 receptor gene markers. Journal of Affective Disorders, 1992, 25, 1-11.	4.1	41
438	Close linkage of bipolar disorder to chromosome 11 markers is excluded in two large Australian pedigrees. Journal of Affective Disorders, 1991, 21, 23-32.	4.1	55
439	Age and depression. Journal of Affective Disorders, 1991, 23, 137-149.	4.1	118
440	Distinguishing psychotic and non-psychotic melancholia. Journal of Affective Disorders, 1991, 22, 135-148.	4.1	57
441	Growth hormone and other hormonal responses to clonidine in melancholic and nonmelancholic depressed subjects and controls. Psychiatry Research, 1991, 37, 179-193.	3.3	8
442	Endocrine and amine responses to D,L-fenfluramine in normal subjects. Psychiatry Research, 1991, 39, 141-153.	3.3	15
443	Psychosocial risk factors distinguishing melancholic and nonmelancholic depression: A comparison of six systems. Psychiatry Research, 1991, 39, 211-226.	3.3	20
444	Treatment of bipolar disorder ^{â^—} . Medical Journal of Australia, 1991, 155, 488-493.	1.7	13
445	Unilateral or bilateral electroconvulsive therapy for depression? A survey of practice and attitudes in Australia and New Zealand. Medical Journal of Australia, 1991, 155, 9-11.	1.7	20
446	Propofol as an Anaesthetic Agent for Ect: Effect on Outcome and Length of Course. Australian and New Zealand Journal of Psychiatry, 1991, 25, 255-261.	2.3	47
447	Depression Sub-Typing: Unitary, Binary or Arbitrary?. Australian and New Zealand Journal of Psychiatry, 1991, 25, 63-76.	2.3	17
448	Psychotic Depression: A Review and Clinical Experience. Australian and New Zealand Journal of Psychiatry, 1991, 25, 169-180.	2.3	68
449	Effect of the anesthetic agent propofol on hormonal responses to ECT. Biological Psychiatry, 1990, 28, 315-324.	1.3	14
450	Hormonal responses to fenfluramine in depressed and control subjects. Journal of Affective Disorders, 1990, 19, 43-51.	4.1	95

#	ARTICLE	IF	CITATIONS
451	Perceived dysfunctional intimate relationships: a specific association with the non-melancholic depressive subtype. Journal of Affective Disorders, 1990, 19, 99-107.	4.1	32
452	The pharmacological management of bulimia nervosa: A critical review. International Journal of Eating Disorders, 1988, 7, 29-41.	4.0	10
453	The law and a physicallyâ€il patient with anorexia nervosa: liberty versus paternalism. Medical Journal of Australia, 1988, 148, 41-44.	1.7	8
454	The Treatment of Bulimia Nervosa. Australian and New Zealand Journal of Psychiatry, 1987, 21, 5-15.	2.3	17
455	The Pharmacological Treatment of Tricyclic-Resistant Depression: Review and Management Guidelines. Australian and New Zealand Journal of Psychiatry, 1987, 21, 442-451.	2.3	3
456	The Establishment of a Mood Disorders Unit. Australian and New Zealand Journal of Psychiatry, 1987, 21, 375-381.	2.3	47
457	Molecular Biology and the Functional Psychoses. Australian and New Zealand Journal of Psychiatry, 1987, 21, 415-418.	2.3	2